Cart
sales@molnova.com
Panitumumab
CAS No. 339177-26-3
Panitumumab( —— )
Catalog No. M22158 CAS No. 339177-26-3
Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 484 | In Stock |
|
| 10MG | 691 | In Stock |
|
| 25MG | 1035 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePanitumumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionPanitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
-
DescriptionPanitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR).
-
In VitroWestern Blot Analysis Cell Line:EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells Concentration:2, 20, 200, 2000 nM Incubation Time:3 h Result:Inhibited ligand-induced autophosphorylation of EGFR.
-
In VivoAnimal Model:NCI-H1975 and NCI-H1650 xenografts Dosage:25, 100, or 500 μg/mouse Administration:Intraperitoneal injection (i.p.), twice a week Result:Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation.Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number339177-26-3
-
Formula Weight147 kDa
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Cohenuram M, et al.Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs. 2007 Jan;18(1):7-15.
molnova catalog
related products
-
PD158780
PD 158780 reversibly inhibits auto and transphosphorylation of all four members of the ErbB receptor superfamily: EGFR ErbB2 ErbB3 and ErbB4 (IC50s: 8μM 49 nM 52 nM and 52 nM in cell assay).
-
DBPR112
DBPR112 is an orally active furanopyrimidine-based EGFR inhibitor with IC50s of 15 nM for EGFRWT and 48 nM for EGFRL858R/T790M, capable of occupying the ATP-binding site and demonstrating significant antitumor efficacy.
-
Afatinib
Afatinib is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity.
